Junshi Biosciences Board Approves 2026 Q1 Report at Fully Attended Meeting

Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has provided an update.

Shanghai Junshi Biosciences Co., Ltd. has disclosed an overseas regulatory announcement in Hong Kong, aligning its Hong Kong disclosure with information released on the Shanghai Stock Exchange. The notice reiterates the company’s compliance with listing rules and outlines the current composition of its board, underscoring a robust governance framework.

The board held the nineteenth meeting of its fourth session on 27 April 2026, with all 14 eligible directors attending and procedures confirmed as lawful and valid. At the meeting, directors reviewed and approved the company’s first quarterly report for 2026, following prior endorsement by the audit committee, signaling continued regulatory compliance and structured financial oversight for stakeholders.

The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.

More about Shanghai Junshi Biosciences Co., Ltd. Class H

Shanghai Junshi Biosciences Co., Ltd. is a China-based biopharmaceutical company listed in Hong Kong and Shanghai. The company focuses on research, development and commercialization of innovative medicines, particularly in oncology and immunology, targeting both domestic and international healthcare markets.

Average Trading Volume: 3,924,048

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$41.62B

For an in-depth examination of 1877 stock, go to TipRanks’ Overview page.